Fig. 7From: Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expressionRANKL‑induced activation of NF‑κB and JNK signaling pathways was attenuated by ZOL treatment in human osteoclast precursor cells (*P value < 0.05 vs. NC group; #P value < 0.05 vs. RANKL group; ^P value < 0.05 vs. RANKL + ZOL + Scramble control group). a Western blot analysis showed ZOL treatment restored the normal expression of genes related to NF‑κB and JNK signaling pathways, while the knockdown of miR-302, miR-101 and miR-145 reversed this situation. b Quantitative analysis of Western blot showed that RANKL induced-upregulation of p-lκBα/lκBα expression was suppressed by ZOL treatment, while the knockdown of miR-302, miR-101 and miR-145 reversed this situation. c Quantitative analysis of Western blot showed that RANKL induced-upregulation of p-p65/p65 expression was suppressed by ZOL treatment, while the knockdown of miR-302, miR-101 and miR-145 reversed this situation. d Quantitative analysis of Western blot showed that RANKL induced-upregulation of p-JNK/JNK expression was suppressed by ZOL treatment, while the knockdown of miR-302, miR-101 and miR-145 reversed this situation. e Quantitative analysis of Western blot showed that RANKL induced-upregulation of p-p38/p38 expression was suppressed by ZOL treatment, while the knockdown of miR-302, miR-101 and miR-145 reversed this situation. f Quantitative analysis of Western blot showed that RANKL induced-upregulation of p-ERK/ERK expression was suppressed by ZOL treatment, while the knockdown of miR-302, miR-101 and miR-145 reversed this situationBack to article page